Robert Seitz
8PUBLICATIONS
68CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.Matteo Dugo, Chiun-Sheng Huang, Daniel Egle
|Nov 16, 2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.Shane R Stecklein, William Barlow, Lajos Pusztai
|Sep 06, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer.Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang
|Apr 06, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz
|Feb 22, 2023
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.Tyler J Nielsen, Matthew G Varga, Catherine T Cronister
|Aug 16, 2022
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.Robert S Seitz, Michael E Hurwitz, Tyler J Nielsen
Pageof 2
Frequent Collaborators
5 joint publications
Brock L Schweitzer
4 joint publications
Tyler J Nielsen
2 joint publications
Pinuccia Valagussa
2 joint publications
Marc Thill
2 joint publications
Lajos Pusztai
2 joint publications
Daniel Egle
2 joint publications
Giampaolo Bianchini
2 joint publications
Lucia Del Mastro
2 joint publications
Kimberly McGregor
2 joint publications
Matthew Gordon Varga
